Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, today announced that on December 15, 2015, the compensation committee of the company’s board of directors granted 41 new employees options to purchase an aggregate of 89,100 shares of the company’s common stock with a per share exercise price of $27.50, the closing trading price on the grant date, and 44,550 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company. (Original Source)
Shares of Relypsa Inc closed yesterday at $28.31, up $0.81 or 2.95%. RLYP has a 1-year high of $42.26 and a 1-year low of $10.26. The stock’s 50-day moving average is $21.99 and its 200-day moving average is $25.81.
On the ratings front, Relypsa has been the subject of a number of recent research reports. In a report issued on December 8, Wedbush analyst Liana Moussatos maintained a Buy rating on RLYP, with a price target of $75, which implies an upside of 164.9% from current levels. Separately, on December 7, Cantor Fitzgerald’s Mara Goldstein maintained a Buy rating on the stock and has a price target of $42.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Liana Moussatos and Mara Goldstein have a total average return of 22.6% and -1.6% respectively. Moussatos has a success rate of 49.3% and is ranked #33 out of 3645 analysts, while Goldstein has a success rate of 43.1% and is ranked #2863.
The street is mostly Bullish on RLYP stock. Out of 7 analysts who cover the stock, 7 suggest a Buy rating . The 12-month average price target assigned to the stock is $52.33, which represents a potential upside of 84.8% from where the stock is currently trading.
Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.